TRV-120027 TFA – Purity ?98% | CAS No. 1234510-46-3 | GMP Supplier (Manufacturer)

TRV-120027 TFA – Purity ?98% | CAS No. 1234510-46-3 | GMP Supplier (Manufacturer)

$2.00

TRV-120027 TFA is a synthetic peptide analog of Ang II, acting as a ?-arrestin-biased agonist at AT1R to promote vasodilation and cardiomyocyte contractility, aimed at heart failure studies. Purity ?98%, GMP-manufactured. Laboratory use only.?For wholesale prices, other specifications and uses, please consult our staff?

EMI starting from $0.00/month - View Plans
Compare
Category:

Description

TRV-120027, also known as TRV027 TFA, is a novel peptide-based analog of angiotensin II that uniquely biases signaling toward ?-arrestin pathways at the angiotensin II type 1 receptor (AT1R), while inhibiting traditional G-protein–mediated vasoconstriction. This pharmacological profile enables simultaneous promotion of vasodilation, enhancement of cardiomyocyte contractility, and anti-apoptotic actions. These effects combine to provide potent cardioprotection, particularly relevant in acute heart failure settings. Developed under GMP conditions with high pharmacological grade purity (?98%), TRV-120027 is an advanced research tool for cardiovascular, renal, and pharmacodynamic investigation.


Product Category

Cardioprotective Biased Ligand Peptides — synthetic peptides that selectively activate signaling bias, used in heart failure, cardiovascular modeling, and receptor-signaling research.


Product Specifications

ParameterDetails
Product NameTRV-120027 TFA
SynonymsTRV027, TRV 120027
CAS Number1234510-46-3
Purity?98.0%
Classification?-arrestin-biased AT1R agonist peptide
Molecular FormulaC??H??N??O??
Molecular Weight?926 Da
Mode of ActionAT1R signaling via ?-arrestin, G-protein pathway blocked
AppearanceWhite to off-white powder
SolubilitySoluble in DMSO and aqueous media
Storage–20 °C; store dry and protected from light
GMP ComplianceYes — produced in GMP-certified facility

Mechanism of Action & Research Applications

TRV-120027 binds AT1R and shifts its signaling from G-protein–mediated vasoconstriction to ?-arrestin–mediated cardioprotective responses. Key actions include:

  • Vasodilation by antagonizing G-protein pathways

  • Enhanced cardiomyocyte contractility via ?-arrestin engagement

  • Anti-apoptotic effects, aiding cell survival in cardiac stress
    In heart failure models, especially when combined with diuretics like furosemide, TRV-120027 reduces cardiac preload and afterload, maintains renal performance, and enhances cardiac output—making it highly relevant for studies on acute heart failure, renal function, and biased agonist pharmacotherapeutics.


Side Effects (For Research Context Only)

Experimental studies show effective hemodynamic targeting at controlled doses. Researchers should monitor cardiovascular markers to avoid hypotension. The ?-arrestin bias limits typical angiotensin II–mediated side effects, but safety monitoring remains essential.


Logistics Transportation

All shipments are insurance-covered to guarantee safe and prompt delivery. We offer 100% compensation for any lost, detained, or damaged items.


Disclaimer

This product is strictly intended for laboratory research use only. It is not approved for therapeutic, clinical, or veterinary purposes.

Additional information

Weight0.8 kg
Dimensions26 × 23 × 26 cm

Reviews

There are no reviews yet.

Be the first to review “TRV-120027 TFA – Purity ?98% | CAS No. 1234510-46-3 | GMP Supplier (Manufacturer)”

Your email address will not be published. Required fields are marked *

EMI Options

Select at least 2 products
to compare